Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Spine BioPharma Completes Enrollment for Phase 3 Trial of SB-01 for Chronic Low Back Pain
Details : SB-01 is a 7-amino acid synthetic peptide that binds to and antagonizes TGF-Beta activity. It is being developed for chronic low back pain in degenerative disc disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 24, 2024
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Recipient : Ensol BioSciences
Deal Size : $155.0 million
Deal Type : Agreement
Spine BioPharma Signs with Ensol BioSciences to Expand Indications for SB-01 Injection
Details : Spine BioPharma acquired the right to develop and commercialize SB-01, excluding Korea. It is being evaluated for the treatment of pain-related disability, associated with Degenerative Disc Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 10, 2024
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Recipient : Ensol BioSciences
Deal Size : $155.0 million
Deal Type : Agreement
Spine BioPharma Announces First Patient Treated in U.S. Phase 3 Clinical Study
Details : SB-01 is a 7-amino acid peptide that binds to and antagonizes TGFβ1 activity. TGFβ1 is an inflammatory cytokine which is often highly expressed in the degenerated discs.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 07, 2022
Lead Product(s) : SB-01
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : MCRA
Deal Size : Inapplicable
Deal Type : Inapplicable
Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine
Details : SB-01 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lumbar Degenerative Disc Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 26, 2022
Lead Product(s) : SB-01
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : MCRA
Deal Size : Inapplicable
Deal Type : Inapplicable
Spine BioPharma Initiating U.S. Phase 3 Clinical Study
Details : SB-01 is a 7-amino acid peptide that binds to and antagonizes TGFβ1 activity, is the first pharmacologic treatment to enter Phase 3 studies for the treatment of pain-related disability, associated with DDD.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 11, 2022
Lead Product(s) : SB-01
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Viscogliosi Bros.
Deal Size : $13.0 million
Deal Type : Series B Financing
Spine BioPharma Completes Series B Financing
Details : The company intends to use the financing to support further development of SB-01 For Injection "SB-01" (formerly referred to as Remedisc™), a first-in-class therapeutic for the treatment of degenerative disc disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 28, 2022
Lead Product(s) : SB-01
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Viscogliosi Bros.
Deal Size : $13.0 million
Deal Type : Series B Financing